EHMT2 and Alzheimer disease: Treatment of transgenic mice with the G9a/GLP inhibitor UNC0642 reduces H3K9me2 and changes the overall levels of 5mC and 5hmC, increasing synaptic plasticity and reducing neuroinflammation, preventing Aβ plaque accumulation and enhancing cognitive function, thereby affecting the development of AD.